Marker Gene acquired by Abcam plc to extend assay and labelling capabilities
On March 4, Marker Gene was acquired by Abcam plc, a global life sciences company that identifies, develops, and distributes high-quality biological reagents and tools crucial to research, drug discovery and diagnostics. Marker Gene brings its deep expertise in the areas of biology, organic synthesis and fluorescence chemistry to enhance Abcam’s current in-house capabilities. Our experience in the creation of detection tools, including proprietary assay development technologies and labeling capabilities, are a compelling addition to the Abcam portfolio. It’s an exciting time for our team at Marker Gene to be joining Abcam as it expands its antibody-conjugation strategy. We are looking forward to leveraging our skills and experience to help drive the creation of a broad range of new products.Our products and services are still available to order from our website and via our other sales channels.
Marker Gene Technologies, Inc and COVID-19